Apyx Medical(APYX)2025-05-08 10:58Revenue Performance - Total revenue for Q1 2025 was $9.4 million, a decrease of 8% compared to $10.2 million in Q1 2024[6] - Advanced Energy segment revenue increased by 6% to $7.9 million, driven by strong generator unit sales and U.S. single-use handpiece sales[4] - OEM revenue decreased by 45% to approximately $1.5 million, down from $2.8 million in the prior year[6] - Financial guidance for full year 2025 projects total revenue between $47.6 million and $49.0 million, with Advanced Energy revenue expected to be $39.6 million to $41.0 million[11] Profitability and Loss - Net loss attributable to stockholders decreased by 45% to $4.2 million, or $0.10 per share, compared to a net loss of $7.6 million, or $0.22 per share, in Q1 2024[9] - Adjusted EBITDA loss improved by 54% to $2.4 million, compared to $5.3 million in the same period last year[10] - The net loss attributable to stockholders for Q1 2025 was $4,150,000, an improvement from a net loss of $7,576,000 in Q1 2024, indicating a reduction of about 45.5%[23] - Adjusted EBITDA for Q1 2025 was reported at $(2,440,000), compared to $(5,337,000) in Q1 2024, reflecting a year-over-year improvement of approximately 54.4%[23] Cost Management - Operating expenses decreased by $3.8 million to $8.7 million, reflecting cost-cutting measures implemented in Q4 2024[8] - Stock-based compensation expense for Q1 2025 was $451,000, down from $1,128,000 in Q1 2024, a decrease of about 60%[23] Asset and Liability Management - As of March 31, 2025, total assets decreased to $60,160,000 from $64,842,000 as of December 31, 2024, representing a decline of approximately 7.5%[20] - Total current assets decreased to $51,851,000 in Q1 2025 from $56,440,000 in Q4 2024, a decrease of about 8.5%[20] - Total liabilities decreased slightly to $49,516,000 in Q1 2025 from $50,507,000 in Q4 2024, a reduction of approximately 2%[20] - Cash and cash equivalents as of March 31, 2025, were $31,011,000, down from $31,741,000 at the end of 2024, a decrease of about 2.3%[20] - The company reported a decrease in trade accounts receivable to $11,645,000 in Q1 2025 from $15,480,000 in Q4 2024, a decline of approximately 24.9%[20] - The accumulated deficit increased to $(82,061,000) as of March 31, 2025, compared to $(77,911,000) at the end of 2024, reflecting an increase of approximately 5.5%[20] - The company’s long-term debt increased to $34,127,000 in Q1 2025 from $33,893,000 in Q4 2024, an increase of about 0.7%[20] Product Development - The company plans to launch the AYON Body Contouring System in the second half of 2025, pending FDA clearance[4] - Renuvion won the 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"[4] Gross Profit Margin - Gross profit margin increased to 60% in Q1 2025, up from 58% in Q1 2024, due to changes in product and geographic mix[7]